Design, synthesis and biological evaluation of 2,4-disubstituted oxazole derivatives as potential PDE4 inhibitors

被引:22
作者
Li, Ya-Sheng [1 ]
Hu, De-Kun [1 ]
Zhao, Dong-Sheng [4 ]
Liu, Xing-Yu [1 ]
Jin, Hong-Wei [5 ]
Song, Gao-Peng [3 ]
Cui, Zi-Ning [1 ,2 ]
Zhang, Lian-Hui [1 ]
机构
[1] South China Agr Univ, Guangdong Prov Key Lab Microbial Signals & Dis Co, Integrat Microbiol Res Ctr, State Key Lab Conservat & Utilizat Subtrop Agrobi, Guangzhou 510642, Guangdong, Peoples R China
[2] Guizhou Univ, Minist Educ, Key Lab Green Pesticide & Agr Bioengn, Guiyang 550025, Peoples R China
[3] South China Agr Univ, Coll Mat & Energy, Guangzhou 510642, Guangdong, Peoples R China
[4] Quanzhou Med Coll, Dept Pharm, Quanzhou 362100, Peoples R China
[5] Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China
基金
中国国家自然科学基金;
关键词
Synthesis; 4-Phenyl-2-oxazole; Pyrazole derivatives; PDE4; inhibitor; Molecular simulation; PHOSPHODIESTERASE-4; INHIBITORS; DISCOVERY; CATECHOLAMIDES; ANTIDEPRESSANT; BIOACTIVITY; ASTHMA;
D O I
10.1016/j.bmc.2017.01.047
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In this study, a series of pyrazole derivatives containing 4-phenyl-2-oxazole moiety were designed and synthesized in a concise way, some of which exhibited considerable inhibitory activity against PDE4B and blockade of LPS-induced INF-alpha release. Compound 4c displayed the strongest inhibition activity (IC50= 1.6 +/- 0.4 mu M) and good selectivity against PDE4B. Meanwhile, compound 4c showed good in vivo activity in animal models of asthma/COPD and sepsis induced by LPS. The primary structure activity relationship study showed the 3,5-dimethylpyrazole residue was essential for the bioactivity, and the substituted group R-1 at the benzene ring also affected the activity. Docking results showed that compound 4c played a key role to form integral hydrogen bonds and a pi-pi stacking interaction, using hydrazide scaffold (-CO-N-N-) and pyrazole ring respectively, with PDE4B protein. While the rest part of the molecule extended into the catalytic domain to block the access of cAMP and formed the foundation for inhibition of PDE4B. Compound 4c would be great promise as a lead compound for further study based on the preliminary structure-activity relationship and molecular modeling studies. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1852 / 1859
页数:8
相关论文
共 24 条
[1]   PRIMARY SEQUENCE OF CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE ISOZYMES AND THE DESIGN OF SELECTIVE INHIBITORS [J].
BEAVO, JA ;
REIFSNYDER, DH .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1990, 11 (04) :150-155
[2]   Phosphodiesterase-4 as a therapeutic target [J].
Houslay, MD ;
Schafer, P ;
Zhang, KYJ .
DRUG DISCOVERY TODAY, 2005, 10 (22) :1503-1519
[3]   Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD [J].
Huang, Zheng ;
Mancini, Joseph A. .
CURRENT MEDICINAL CHEMISTRY, 2006, 13 (27) :3253-3262
[4]   Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development [J].
Jeon, YH ;
Heo, YS ;
Kim, CM ;
Hyun, YL ;
Lee, TG ;
Ro, S ;
Cho, JM .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2005, 62 (11) :1198-1220
[5]   Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease [J].
Kodimuthali, Arumugam ;
Jabaris, S. Sugin Lal ;
Pal, Manojit .
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (18) :5471-5489
[6]   Discovery of a highly potent series of oxazole-based phosphodiesterase 4 inhibitors [J].
Kuang, Rongze ;
Shue, Ho-Jane ;
Blythin, David J. ;
Shih, Neng-Yang ;
Gu, Danlin ;
Chen, Xiao ;
Schwerdt, John ;
Lin, Ling ;
Ting, Pauline C. ;
Zhu, Xiaohong ;
Aslanian, Robert ;
Piwinski, John J. ;
Xiao, Li ;
Prelusky, Daniel ;
Wu, Ping ;
Zhang, Ji ;
Zhang, Xiang ;
Celly, Chander S. ;
Minnicozzi, Michael ;
Billah, Motasim ;
Wangd, Peng .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (18) :5150-5154
[7]   Discovery of oxazole-based PDE4 inhibitors with picomolar potency [J].
Kuang, Rongze ;
Shue, Ho-Jane ;
Xiao, Li ;
Blythin, David J. ;
Shih, Neng-Yang ;
Chen, Xiao ;
Gu, Danlin ;
Schwerdt, John ;
Lin, Ling ;
Ting, Pauline C. ;
Cao, Jianhua ;
Aslanian, Robert ;
Piwinski, John J. ;
Prelusky, Daniel ;
Wu, Ping ;
Zhang, Ji ;
Zhang, Xiang ;
Celly, Chander S. ;
Billah, Motasim ;
Wang, Peng .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (07) :2594-2597
[8]   Synthesis and bioactivity of pyrazole and triazole derivatives as potential PDE4 inhibitors [J].
Li, Ya-Sheng ;
Tian, Hao ;
Zhao, Dong-Sheng ;
Hu, De-Kun ;
Liu, Xing-Yu ;
Jin, Hong-Wei ;
Song, Gao-Peng ;
Cui, Zi-Ning .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (15) :3632-3635
[9]   The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in cynomolgus monkeys [J].
Losco, PE ;
Evans, EW ;
Barat, SA ;
Blackshear, PE ;
Reyderman, L ;
Fine, JS ;
Bober, LA ;
Anthes, JC ;
Mirro, EJ ;
Cuss, FM .
TOXICOLOGIC PATHOLOGY, 2004, 32 (03) :295-308
[10]   The next generation of phosphodiesterase inhibitors: Structural clues to ligand and substrate selectivity of phosphodiesterases [J].
Manallack, DT ;
Hughes, RA ;
Thompson, PE .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (10) :3449-3462